AbbVie Inc. (ABBV)

NYSE • Currently up 1.94 (+0.73%) in today's trading session

32 members of Congress have disclosed 100 trades in AbbVie Inc. (ABBV) via STOCK Act filings. The most recent disclosure was a sale by Pete Sessions on 14 September 2026. The most active traders have been Kathy Manning (10), Marjorie Taylor Greene (9), and Julia Letlow (7). Aggregate disclosed activity totals roughly $688K in purchases and $602.5K in sales (midpoint estimates from bracketed disclosure amounts).

AbbVie Inc. is currently trading at $266.28, positioned at 96% of its 52-week range ($190.75 – $269.39).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$266.28
24h Change
+1.94 (+0.73%)
52 Week Range
$190.75–$269.39
View on NASDAQ

AbbVie Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ABBV

Select to highlight on chart
5 transactions
Compliance: 64%
Pete Sessions14 Sept 202618 Sept 2026SaleStock$15,001 - $50,000N/A
Josh Gottheimer5 May 20263 Jun 2026SaleStock$1,001 - $15,000N/A
Julie Johnson18 Dec 202515 Jan 2026SaleStock$1,001 - $15,000N/A
Julia Letlow8 Dec 202513 Jan 2026SaleStock$1,001 - $15,000N/A
Julie Johnson13 Nov 202511 Dec 2025SaleStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$467.85B

Volume

3.55M

Beta

0.28

P/E Ratio

26.14

Fundamentals

EPS

$10.19

Div. Yield

2.56%

Open

$264.38

Day Range

$263.38 – $267.74

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE · USD
Country
US
CEO
Robert A. Michael
IPO Date
2013-01-02
Website
www.abbvie.com

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Lea...

Earnings

Next Report

Q3 2026

30 Oct

EPS Est.

$3.86

Rev. Est.

$17.3B

Days Until

32

Recent Quarters

Q2 202631 Jul
EPS$3.65
Beat 1.1%
Q1 202629 Apr
EPS$2.65
Beat 2.3%
Q4 20254 Feb
EPS$2.71
Beat 2.3%
Q3 202531 Oct
EPS$1.86
Beat 5.1%
Q2 202531 Jul
EPS$2.97
Beat 3.1%
Q1 202525 Apr
EPS$2.46
Beat 3.4%
Q4 202431 Jan
EPS$2.16
Miss 27.5%
Q3 202430 Oct
EPS$3.00
Beat 2.7%
Q2 202425 Jul
EPS$2.65
Beat 3.1%
Q1 202426 Apr
EPS$2.31
Beat 2.2%
Q4 20232 Feb
EPS$2.79
Beat 1.1%
Q3 202327 Oct
EPS$2.95
Beat 3.1%
Q2 202327 Jul
EPS$2.91
Beat 4.3%
Q1 202327 Apr
EPS$2.46
Beat 0.8%
Q4 20229 Feb
EPS$3.60
Beat 1.7%
Q3 202228 Oct
EPS$3.66
Beat 2.8%
Q2 202229 Jul
EPS$3.37
Beat 1.8%
Q1 202229 Apr
EPS$3.24
Beat 3.2%
Q4 20212 Feb
EPS$3.31
Beat 0.6%
Q3 202129 Oct
EPS$3.33
Beat 3.1%
Q2 202130 Jul
EPS$3.11
Beat 0.0%
Q1 202130 Apr
EPS$2.95
Beat 6.5%
Q4 20203 Feb
EPS$2.92
Beat 2.5%
Q3 202030 Oct
EPS$2.83
Beat 2.9%
Q2 202031 Jul
EPS$2.34
Beat 4.5%
Q1 20201 May
EPS$2.42
Beat 7.6%
Q4 20197 Feb
EPS$2.21
Beat 0.9%
Q3 20191 Nov
EPS$2.33
Beat 1.8%
Q2 201926 Jul
EPS$2.26
Beat 2.3%
Q1 201925 Apr
EPS$2.14
Beat 4.4%
Q4 201825 Jan
EPS$1.90
Miss 1.0%
Q3 20182 Nov
EPS$2.14
Beat 5.9%
Q2 201827 Jul
EPS$2.00
Beat 1.0%
Q1 201826 Apr
EPS$1.87
Beat 4.5%
Q4 201726 Jan
EPS$1.48
Beat 2.8%
Q3 201727 Oct
EPS$1.41
Beat 1.4%
Q2 201728 Jul
EPS$1.42
Beat 1.4%
Q1 201727 Apr
EPS$1.28
Beat 1.6%
Q4 201627 Jan
EPS$1.20
Beat 0.0%
Q3 201628 Oct
EPS$1.21
Beat 0.8%
Q2 201629 Jul
EPS$1.26
Beat 5.0%
Q1 201628 Apr
EPS$1.15
Beat 2.7%
Q4 201529 Jan
EPS$1.13
Beat 0.9%
Q3 201530 Oct
EPS$1.13
Beat 5.6%
Q2 201524 Jul
EPS$1.08
Beat 1.9%
Q1 201523 Apr
EPS$0.94
Beat 11.9%
Q4 201430 Jan
EPS$0.89
Beat 4.7%
Q3 201431 Oct
EPS$0.89
Beat 14.1%
Q2 201425 Jul
EPS$0.82
Beat 7.9%
Q1 201425 Apr
EPS$0.71
Beat 4.4%
Q4 201331 Jan
EPS$0.82
Beat 0.0%
Q3 201325 Oct
EPS$0.82
Beat 5.1%
Q2 201326 Jul
EPS$0.82
Beat 3.8%
Q1 201326 Apr
EPS$0.68
Beat 1.5%
Q4 201215 Mar
EPS$0.96
Q4 201223 Jan
EPS$1.00
Beat 1.0%
Q1 201230 Jun
EPS$0.78
Q4 201131 Mar
EPS$0.54
Q3 201131 Dec
EPS$0.73
Q2 201130 Sept
EPS$0.01
Q1 201130 Jun
EPS$0.97
Q4 201031 Mar
EPS$0.45

52 politicians traded within 30 days

Dividends

Next Dividend

Ex-Date

15 Oct 2026

Amount

$1.7300 per share

Yield

2.62%

Days Until

17

Pay Date:16 Nov 2026
Record Date:15 Oct 2026
Declared:10 Sept 2026

Dividend History

15 Jul 2026
Amount $1.7300
15 Apr 2026
Amount $1.7300
16 Jan 2026
Amount $1.7300
15 Oct 2025
Amount $1.6400
15 Jul 2025
Amount $1.6400
15 Apr 2025
Amount $1.6400
15 Jan 2025
Amount $1.6400
15 Oct 2024
Amount $1.5500
15 Jul 2024
Amount $1.5500
12 Apr 2024
Amount $1.5500
12 Jan 2024
Amount $1.5500
12 Oct 2023
Amount $1.4800
13 Jul 2023
Amount $1.4800
13 Apr 2023
Amount $1.4800
12 Jan 2023
Amount $1.4800
13 Oct 2022
Amount $1.4100
14 Jul 2022
Amount $1.4100
13 Apr 2022
Amount $1.4100
13 Jan 2022
Amount $1.4100
14 Oct 2021
Amount $1.3000
14 Jul 2021
Amount $1.3000
14 Apr 2021
Amount $1.3000
14 Jan 2021
Amount $1.3000
14 Oct 2020
Amount $1.1800
14 Jul 2020
Amount $1.1800
14 Apr 2020
Amount $1.1800
14 Jan 2020
Amount $1.1800
11 Oct 2019
Amount $1.0700
12 Jul 2019
Amount $1.0700
12 Apr 2019
Amount $1.0700
14 Jan 2019
Amount $1.0700
12 Oct 2018
Amount $0.9600
12 Jul 2018
Amount $0.9600
12 Apr 2018
Amount $0.9600
11 Jan 2018
Amount $0.7100
12 Oct 2017
Amount $0.6400
12 Jul 2017
Amount $0.6400
11 Apr 2017
Amount $0.6400
11 Jan 2017
Amount $0.6400
12 Oct 2016
Amount $0.5700
13 Jul 2016
Amount $0.5700
13 Apr 2016
Amount $0.5700
13 Jan 2016
Amount $0.5700
13 Oct 2015
Amount $0.5100
13 Jul 2015
Amount $0.5100
13 Apr 2015
Amount $0.5100
13 Jan 2015
Amount $0.4900
10 Oct 2014
Amount $0.4200
11 Jul 2014
Amount $0.4200
11 Apr 2014
Amount $0.4200
13 Jan 2014
Amount $0.4000
10 Oct 2013
Amount $0.4000
11 Jul 2013
Amount $0.4000
11 Apr 2013
Amount $0.4000
11 Jan 2013
Amount $0.4000

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

JNJ

Johnson & Johnson

74
$271.95+0.73 (+0.27%)
Healthcare
7 politicians hold this stock
Same sector: Healthcare
+1 more reason
7 politicians
View Stock

MSFT

Microsoft Corporation

48
$509.22-6.95 (-1.35%)
Technology
8 politicians hold this stock
Significant holdings value
8 politicians
View Stock

AMZN

Amazon.com, Inc.

48
$246.15-3.52 (-1.41%)
Consumer Cyclical
8 politicians hold this stock
Significant holdings value
8 politicians
View Stock

Frequently Asked Questions about ABBV

Which members of Congress have traded ABBV?
32 members of Congress have disclosed 100 trades in AbbVie Inc. (ABBV) under the STOCK Act. The most active traders are Kathy Manning, Marjorie Taylor Greene, and Julia Letlow.
When was ABBV most recently disclosed by Congress?
The most recent ABBV disclosure was a sale by Pete Sessions on 14 September 2026.
What is the total disclosed congressional trading volume for ABBV?
Members of Congress have disclosed approximately $688K in ABBV purchases and $602.5K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ABBV?
This ABBV page updates as soon as new STOCK Act disclosures are filed for AbbVie Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.